Palvella Therapeutics, Inc. (NasdaqGM: PVLA)
Health Care · Biotechnology · US
$148.24
+1.71% today · +175.8% 1Y
Palvella Therapeutics, Inc. (NasdaqGM: PVLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.14B and employs 29 people.
Over the last twelve months the share price has gained 175.8%, trading between 49.13 and 161.38.
Tweenvest scores Palvella Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
PVLA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.14B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.90
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $161.38
- 52-week low
- $49.13
- Avg volume (3M)
- —
- Shares outstanding
- 14.41M
- Employees
- 29
- Next earnings
- —
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
- ISIN
- US6979471090
- Listed since
- Jan 2, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.